In line with its 2024-2025 regulatory agenda, Brazil’s drug regulator Anvisa is preparing to establish a regulatory sandbox to bring innovation to patients more quickly. The agency is consulting on a 247-page regulatory impact analysis report with a view to ensuring that the final sandbox model is effective.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?